Neurofit is a preclinical Contract Research Organization (CRO) based in Illkirch Graffenstaden, France, that specializes in the evaluation of treatments for central and peripheral nervous system (CNS and PNS) disorders. Its services include validated in vivo and in vitro disease and safety models for drug screening.
Neurofit also provides several inflammation models.

Founded in 1996, Neurofit has 30 years of experience serving the biopharmaceutical industry with neuroscience research models. Its core scientific team has longstanding collaborative experience, helping provide consistency and depth in study design. Our team of scientists benefits from ongoing training to always deliver cutting-edge services.

Yes. Neurofit maintains rigorous standards of data integrity and quality control, ensuring that all preclinical data is robust, reproducible, and suitable for submissions to global regulatory bodies such as the FDA and EMA.

Neurofit is strictly committed to the 3Rs (Replacement, Reduction, Refinement) and maintains high standards of animal welfare through the following practices:

Refinement

We prioritize the well-being of our subjects through social group housing, comprehensive environmental enrichment programs, and proactive pain management. Furthermore, all staff undergo continuous specialized training to ensure the highest level of care.

Reduction

To minimize the number of animals used, we utilize subjects as their own internal controls whenever possible. We apply rigorous statistical design to define the smallest possible group size (n) that still ensures robust statistical power. We also maximize data collection through the use tissue samples for analytical and biochemical analyses.

Replacement

We utilize advanced in vitro models, such as primary neuronal cultures and co-cultures, to effectively screen compounds and reduce the necessity for initial in vivo testing.

Sex as a Biological Variable: We are actively working on the consideration of sex effects in our research models to ensure more inclusive and scientifically accurate data.

Neurofit ensures reliability through validated protocols, reproducible data, and a commitment to technical precision. Our approach to quality focuses on the integrity of our results and transparent communication at every stage of the project.
What truly sets Neurofit apart is the depth of our specialized know-how. Our models and assays are not just off-the-shelf procedures; they have been meticulously performed and perfected in-house by our team of veteran scientists.

Neurofit offers a broad range of models and assays covering neurological and psychiatric conditions - including Alzheimer’s disease, Parkinson’s disease, epilepsy, anxiety, depression, multiple sclerosis, neuropathic pain and peripheral neuropathies - using both behavioral and cellular models. Complementing these are inflammatory models applicable to arthritis, allergy, and other systemic inflammatory conditions.

Neurofit’s portfolio includes:

Animal behavioral

Animal behavioral testing associated with disease models (e.g., cognition, anxiety/depression, sensorimotor pain).

Electrodiagnostics

Electrodiagnostics such as electromyography (EMG) and nerve conduction studies.

Cellular assays

Cellular assays like neurite outgrowth and survival tests

Histomorphometry and morphological measures

These tools help screen compounds for neuroprotective, neurotoxic, and other effects.

Neurofit’s studies are scientifically rigorous and aligned with industry standards.

Neurofit offers validated and clinically relevant models, selected to optimize predictive value for human disease mechanisms. The company also provides extensive validation data and works closely with clients to recommend the most suitable models for their research goals.
Please contact us at neurofit@neurofit.com to gain access to our validation data.

Neurofit provides sample collection (e.g., blood, serum) and dissection of brain microstructures. Neurofit can provide histological analysis or send the samples to a third party for pharmacokinetic, biochemical, or immunochemical analyses.

Yes. Our surgical team is expert in stereotaxic injections, and specific nerve lesions, enabling targeted drug delivery and the creation of precise disease models for CNS and PNS research. Our surgery procedures are validated by a veterinarian and follow high standard: aseptic process, antalgic and analgesic medication, body temperature control, carful monitory from sleep onset to awakening.

Neurofit can be contacted through its contact form and direct email at neurofit@neurofit.com , where teams provide quotes, discuss custom protocols, and offer support for initiating projects.

Neurofit offers both behavioral animal models and cellular assays that combine proven methodologies with automation and state-of-the-art videotracking for next-level precision. Neurofit holds several permits from the ANSM (French regulatory agency) to test regulated substances and supports industry leaders in the rigorous assessment of their compounds (Publications)
Neurofit routinely uses the intranasal administration route to facilitate chronic treatment protocols and allow molecules to directly target the brain (click for more information: newsletter 68 and flyer ).
Neurofit has developed a translational CCK model for Panic Anxiety–Associated Cognitive Impairment. (click for more information: newsletter 127)
Neurofit supports innovative programs exploring the neuroprotective effects of GLP-1 agonists (such as semaglutide) and the neuroplastic potential of psilocybin-based therapies (psychedelics and other serotonergic modulators). We provide specialized readouts to evaluate these compounds in models of neurodegeneration and psychiatric disorders (find out more: newsletter 108)

Clients benefit from direct access to our Ph.D.-level scientists, Emile Andriambeloson (Head of Research) and Stéphanie Wagner (Head of Neurobiology), who provide consultative support to optimize study protocols, select the most relevant models, and ensure that the experimental design aligns with preclinical goals.

The best way to understand why clients choose us is to hear it directly from some of them:

“One of the best CROs I have had the pleasure working with. Feedback is always prompt, studies completed on time, and results always delivered on time without prompting. Always a great experience.”
“I would like to thank NEUROFIT especially you for the very nice time working with you; it felt like a really nice colleague”
“Thanks for providing convincing and comprehensive experimental results which really helps the team as we are trying to address the feedback resulting from the publication. We really appreciate and value your expertise, thoughtfulness and ability to produce a well-controlled study”
“Let me state again how happy we are with the data and the quality of the results”

The company continuously updates its models, integrates new technologies, initiates pilot studies, and invests in R&D to stay at the forefront of research.

Neurofit maintains a scientific corner on its website with access to its latest Newsletters, Posters, Validation Data, and Publications. To sign up to our newsletter and receive scientific input monthly, click here

... and maintain its technical excellence?

Neurofit is deeply committed to academic excellence and the advancement of the neuroscience community. As part of our contribution to the next generation of experts, we host Master’s and BTS (Higher Technical Certificate) students for intensive, mentorship-based internships. This program is a philanthropic effort to bridge the gap between academic theory and industry standards, allowing students to observe and learn within a professional preclinical environment.
To maintain our technical excellence for contract studies, Neurofit implements a specialized, rigorous training program exclusively for our permanent staff. We also maintain active relationships with surgical experts, university professors, and industrial leaders. By fostering these high-level connections through deep technical discussions and ongoing collaborations, we ensure our expert team remains at the forefront of preclinical research, delivering reliable data backed by years of industrial experience.

The company continuously updates its models, integrates new technologies, initiates pilot studies, and invests in R&D to stay at the forefront of CNS research.

Absolutely. Neurofit’s expertise is documented across a wide range of peer-reviewed publications available in major scientific databases. These articles, produced in synergy with leading academic researchers and Big Pharma partners, provide a transparent look at our technical capabilities and our commitment to advancing the understanding of neurodegenerative and neuromuscular pathologies.
Neurofit’s publications include articles in collaboration with Ipsen, Ceres Brain, Bionomics, Cognigenics, 3Z-Pharma, CEA, Servier, Solvay To gain access to the publications, please click: Publications.

Neurofit’s research and development is led by a distinguished team of Head Scientists, Dr. Emile Andrianbeloson and Dr. Stéphanie Wagner. With over 25 years of dedicated industry experience in preclinical neuroscience, they provide the strategic and technical vision for the company.
Their leadership ensures that every protocol and specialized readout we develop is grounded in proven scientific excellence and industrial-grade rigor. Having refined our disease models over two decades, our scientific leadership offers clients a unique depth of expertise in successfully navigating the complexities of drug screening and early development.